Literature DB >> 31545782

Cutaneous leishmaniasis associated with Systemic Lupus Erythematosus (SLE).

Qasem Asgari1, Fatemeh Gholizadeh2, Mohammad Nohtani1, Mehdi Mirzaeipour1, Mehdi Zare3, Mohammad Saleh Bahreini1.   

Abstract

Cutaneous Leishmaniasis (CL) is a protozoan disease caused by Leishmania spp. and is endemic in the Americas, the Mediterranean basin, Middle East, and Central Asia. There are reports regarding the co-infection of CL with other diseases, especially immune system disorders. Herein, we presented a patient with several leishmania lesions who suffered from Systemic Lupus Erythematosus (SLE). He was a 22-year-old man from Fars province, southern Iran who was treated with corticosteroid drugs to control the manifestations of SLE. The presence of leishmanial bodies was confirmed by microscopic and molecular methods. Treatment was performed based on sodium antimony gluconate (1.5 mg/5ml) for three weeks, resulting in acceptable outcomes. However, recurrence of the lesions was observed after two months when the medication was discontinued. This was the first report of Zoonotic Cutaneous Leishmaniasis (ZCL) in an SLE patient.

Entities:  

Mesh:

Year:  2019        PMID: 31545782

Source DB:  PubMed          Journal:  Infez Med        ISSN: 1124-9390


  1 in total

1.  The level of interleukin-17, 23, and gamma interferon in cutaneous leishmaniasis patients before and after intra lesion treatment.

Authors:  Mehdi Ghazanfari; Bahador Shahriari; Vahid Rahnama; Meisam Khazaei; Shahrbanou Naderi; Mohammad Hossein Motazedian
Journal:  J Parasit Dis       Date:  2022-02-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.